mLife · 2026
Targeting homologous recombination repair to potentiate fluoroquinolone efficacy in Mycobacterium abscessus.
Письмо в редакциюНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Shuai, Alam Md Shah, Yusuf Buhari, Zhang Jingran, Lu Ziwen, Zhang Xiaofan, Hameed H M Adnan, Khatun Mst Sumaia, Li Chunyu, Li Lijie, Vatlin Aleksey A, Belachew Aweke M, Tian Xirong, Gao Yamin, Fang Cuiting, Zhang Rogers P, Li Jun, Wang Xinyue, Feng Liqiang, Wan Li, Zhang Tianyu
Аннотация
Fluoroquinolones (FQs) are important for treating fast-growing mycobacterial infections; however, their efficacy can be limited by intrinsic resistance and the emergence of acquired resistance. FQs induce lethal DNA double-strand breaks (DSBs) by targeting topoisomerases. Through a transposon screen in Mycobacterium abscessus, we identified that disruption of adnB, a homologous recombination (HR) gene, markedly sensitized the pathogen to FQs. Subsequent study showed that deleting core HR components (adnB, recO, recA, recR, and ruvB) increased FQs' susceptibility, while other DSB repair pathways (single-strand annealing or non-homologous end joining) had no effect, demonstrating a unique reliance on HR for FQs' tolerance. Complementation with native or its homolog genes restored the resistance phenotype, indicating a conserved HR-dependent tolerance mechanism in M. abscessus. In a murine model, genetic HR abrogation significantly improved FQs' therapeutic efficacy. These results highlight HR repair as a potential therapeutic target to potentiate FQs' activity and combat drug resistance in M. abscessus infections.